Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden

Journal of Cystic Fibrosis

Volumn 8, Issue 2, 2009, Pages 135-142

  Knudsen, Per Kristian ^a   Olesen, Hanne V ^b   Høiby, Niels ^c   Johannesson, Marie ^d   Karpati, Ferenc ^e   Laerum, Birger N ^f   Meyer, Peter ^g   Pressler, Tacjana ^c   Lindblad, Anders ^h  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibiotic therapy; Cystic fibrosis; Prevalence; Pseudomonas aeruginosa

Indexed keywords

ACETYLCYSTEINE; AZITHROMYCIN; BROMHEXINE; CIPROFLOXACIN; COLISTIN; DORNASE ALFA; MACROLIDE; STEROID; TOBRAMYCIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DENMARK; FEMALE; GEOGRAPHIC DISTRIBUTION; GRAM NEGATIVE INFECTION; HUMAN; LUNG FUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORWAY; PANCREAS INSUFFICIENCY; PREVALENCE; PSEUDOMONAS AERUGINOSA; SWEDEN; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; AMBULATORY CARE FACILITIES; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; CYSTIC FIBROSIS; DENMARK; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NORWAY; PREVALENCE; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SPUTUM; SWEDEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 60449108922     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2008.11.001     Document Type: Article

References (36)

1. FitzSimmons S.C. The changing epidemiology of cystic fibrosis. J Pediatr 122 (1993) 1-9
2. Cystic Fibrosis Foundation. Patient Registry 2005 Annual Report (2006), Cystic Fibrosis Foundation, Bethesda, Maryland
3. Li Z., Kosorok M.R., Farrell P.M., Laxova A., West S.E., Green C.G., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293 (2005) 581-588
4. Ballmann M., Rabsch P., and von der H.H. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 53 (1998) 732-737
5. Emerson J., Rosenfeld M., McNamara S., Ramsey B., and Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34 (2002) 91-100
6. Henry R.L., Mellis C.M., and Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 12 (1992) 158-161
7. Frederiksen B., Koch C., and Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23 (1997) 330-335
8. Ratjen F., Doring G., and Nikolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 358 (2001) 983-984
9. Valerius N.H., Koch C., and Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338 (1991) 725-726
10. Wiesemann H.G., Steinkamp G., Ratjen F., Bauernfeind A., Przyklenk B., Döring G., et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 25 (1998) 88-92
11. Marchetti F., and Bua J. More evidence is needed in the antibiotic treatment of Pseudomonas aeruginosa colonisation. Arch Dis Child 90 (2005) 1204
12. Hollsing A.E., Granstrom M., Vasil M.L., Wretlind B., and Strandvik B. Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. J Clin Microbiol 25 (1987) 1868-1874
13. Hoiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl (1977) 1-96
14. Pedersen S.S., Espersen F., and Hoiby N. Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol 25 (1987) 1830-1836
15. Griffiths A.L., Jamsen K., Carlin J.B., Grimwood K., Carzino R., Robinson P.J., et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am J Respir Crit Care Med 171 (2005) 1020-1025
16. Jones A.M., Dodd M.E., Govan J.R., Doherty C.J., Smith C.M., Isalska B.J., et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center. Am J Respir Crit Care Med 171 (2005) 257-260
17. Panagea S., Winstanley C., Walshaw M.J., Ledson M.J., and Hart C.A. Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces. J Hosp Infect 59 (2005) 102-107
18. Fluge G., Ojeniyi B., Hoiby N., Digranes A., Ciofu O., Hunstad E., et al. Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients. Clin Microbiol Infect 7 (2001) 238-243
19. Ojeniyi B., Frederiksen B., and Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 29 (2000) 177-181
20. Speert D.P., Campbell M.E., Henry D.A., Milner R., Taha F., Gravelle A., et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am J Respir Crit Care Med 166 (2002) 988-993
21. Tubbs D., Lenney W., Alcock P., Campbell C.A., Gray J., and Pantin C. Pseudomonas aeruginosa in cystic fibrosis: cross-infection and the need for segregation. Respir Med 95 (2001) 147-152
22. Ramsey B.W. To cohort or not to cohort: how transmissible is Pseudomonas aeruginosa. Am J Respir Crit Care Med 166 (2002) 906-907
23. Solymar L., Aronsson P.H., Bake B., and Bjure J. Nitrogen single breath test, flow-volume curves and spirometry in healthy children, 7-18 years of age. Eur J Respir Dis 61 (1980) 275-286
24. Quanjer P.H., and Tammeling G.J. Summary of recommendations. Standardized lung function testing. Report Working Party, European Community for Coal and Steel. Bull Eur Physiopathol Respir 19 (1983) 7-10
25. Koch C., Cuppens H., Rainisio M., Madessani U., Harms H., Hodson M., et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 31 (2001) 1-12
26. Hoiby N. Cross-reactions between Pseudomonas aeruginosa and thirty-six other bacterial species. Scand J Immunol 4 (1975) 187-196
27. Hoiby N., Collins M.T., Espersen F., Hertz J.B., Hoff G.E., and Schiotz P.O. Taxonomic application of crossed immunoelectrophoresis. Int J Syst Bacteriol 37 (1987) 229-240
28. Johansson E., Welinder-Olsson C., Lindblad A., Gilljam M., Johannesson M., Meyer P., et al. Genomic fingerprinting of Pseudomonas aeruginosa isolates from all Swedish CF Centres. A Scandinavian Cystic Fibrosis Study Consortium study. J Cyst Fibros 6 S26 (2007) 105
29. Meyer P., Johansson E., Welinder-Olsson C., Lindblad A., Hjelte L., and Karpati F. Pseudomonas aeruginosa transmission at a winter camp in spite of rigorous precautions. J Cyst Fibros 6 S28 (2007) 114
30. Johnson C., Butler S.M., Konstan M.W., Morgan W., and Wohl M.E. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 123 (2003) 20-27
31. Ronne H.C., Pressler T., Hoiby N., and Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros 5 (2006) 245-251
32. Navarro J., Rainisio M., Harms H.K., Hodson M.E., Koch C., Mastella G., et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 18 (2001) 298-305
33. Halfhide C., Evans H.J., and Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev (2005) CD003428
34. Henke M.O., and Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev 8 (2007) 24-29
35. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg L.A., Moss R.B., and Herzenberg L.A. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A 103 (2006) 4628-4633
36. Stafanger G., Garne S., Howitz P., Morkassel E., and Koch C. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J 1 (1988) 161-167